Research
STRENGTHENING AND BUILDING THE FIELD OF MELANOMA RESEARCH Hosted 25th anniversary blog series to highlight MRF-funded researchers, including:
Kieran Smalley, PhD Melanoma Field Needs a Pipeline of Talented Young Scientists
Samantha Black Improving Melanoma
Richard D. Carvajal, MD Encouraging Progress in the Uveal Melanoma Field Screening Education for Primary Care Providers Serving Patients with Skin of Color
Genevieve Boland, MD, PhD and Keith Flaherty, MD The Impact of Research on Improving Patient Outcomes
Douglas B. Johnson, MD, MSCI Managing Immunotherapy- Related Side Effects
LATEST PUBLICATION IN CLINICAL CANCER RESEARCH : The State of Melanoma: Emergent Challenges and Opportunities
UPCOMING MEETINGS: • PD1/PDL1 resistance: a workshop bridging researchers in lung, kidney and melanoma cancers to design clinical trials for patients for whom initial anti-PD1/PDL1 therapies have failed • Melanoma brain metastases: the third MRF-sponsored summit will continue to build upon the foundation of the previous two summits resulting in strategies published in major journals • Defining pre-diagnostic tools for pigmented skin lesions
1998
2021
FDA approves IL-2 as the first immunotherapy for metastatic melanoma.
16 FDA-approved treatments are available, with more currently in development.
TIMELINE
4
Made with FlippingBook Ebook Creator